SPRAVATO® (esketamine) is a prescription nasal spray designed for adults with treatment-resistant depression. Unlike conventional antidepressants, which take weeks to show results, SPRAVATO® targets specific brain receptors to relieve depressive symptoms more quickly. It’s used alongside an oral antidepressant under medical supervision.
Key benefits of SPRAVATO®:
This treatment provides new possibilities for those who haven’t found relief with traditional therapies.
Mental health conditions, particularly treatment-resistant depression, can severely impact everyday life, causing emotional distress, poor job performance, and strained relationships. Seeking timely treatment with SPRAVATO® can:
SPRAVATO® is ideal for individuals who:
At Access Health Services, your SPRAVATO® treatment will occur in a supervised medical setting to ensure safety and comfort. Here’s what the process looks like:
You’ll have access to our compassionate team throughout your treatment, ensuring that you feel supported at every step of your journey.
At Access Health Services, we are committed to helping patients with treatment-resistant depression through modern therapies like SPRAVATO®. Here’s why patients trust us:
Don’t let treatment-resistant depression control your life—book a SPRAVATO® appointment today and explore how this innovative therapy can help you find relief.
SPRAVATO® works by targeting the NMDA receptor in the brain, providing faster symptom relief than traditional antidepressants, which can take weeks to be effective.
The duration and frequency will depend on your progress. Initial therapies are typically administered twice a week, gradually reducing over time as symptoms improve.
Common side effects include dizziness, nausea, and drowsiness. That’s why all SPRAVATO® sessions are supervised in a medical setting to ensure patient safety.
No. Due to potential side effects like drowsiness, patients are prohibited from driving for 24 hours following their treatment session.